KN019 (belatacept biosimilar) / Alphamab - LARVOL DELTA

Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (clinicaltrials.gov) - P2 | N=145 | Completed | Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Unknown status ➔ Completed | Trial completion date: Jun 2021 ➔ Jul 2022 | Trial primary completion date: Apr 2021 ➔ Jul 2022

Trial completion • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights (PRNewswire) - "Alphamab Oncology...reported financial results for the full year ended December 31, 2021 and highlighted recent progress and upcoming milestones....The phase II clinical trial of KN019 for the treatment of rheumatoid arthritis completed the patient enrollment. The final analysis of clinical results is expected to be completed in the first half of 2022. In 2021, we initiated a clinical study on the bioavailability of KN019 in the switch from intravenous infusion to subcutaneous administration."

Enrollment closed • P2 data • Trial status • Immunology • Rheumatoid Arthritis

Alphamab Oncology Reports 2021 Interim Results and Business Highlights (Alphamab Press Release) - "The phase II clinical trial of KN019 for the treatment of rheumatoid arthritis progressed smoothly and completed the enrollment of patients. The interim clinical results are expected to publish in the second half of 2021."

Enrollment closed • P2 data • Immunology • Rheumatoid Arthritis

Alphamab completes phase II first patient dosing of KN019 for RA (GBI Health) - "Suzhou-based biotech Alphamab Oncology (9966.HK) announced first patient dosing in a Phase II clinical study for cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) immunosuppressive fusion protein KN019. The study is designed to assess the efficacy and safety of said drug in active rheumatoid arthritis (RA) patients unresponsive to methotrexate."

Enrollment open

Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (clinicaltrials.gov) - P2; N=141; Recruiting; Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (clinicaltrials.gov) - P2; N=141; Not yet recruiting; Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Clinical • New P2 trial